drugset / Trial / NCT01112072

Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia

NCT01112072

Phase 3 Unknown 160 enrolled Cornea and Laser Eye Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will determine the efficacy of corneal collagen crosslinking (CXL) combined with Intacs for the treatment of keratoconus and corneal ectasia. The goal of CXL is to decrease the progression of keratoconus, while Intacs has been shown to decrease corneal steepness in keratoconus. This study will attempt to determine the relative efficacy of the two procedures either performed at the same session versus CXL performed 3 months after Intacs.

Timeline

Start
2010-04
Primary completion
2024-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Riboflavin Other / unclassified Topical